Dr Leeza Osipenko

Dr Leeza Osipenko

Senior Lecturer in Practice

Department of Health Policy

020 7955 6610
Room No
COW 1.07
Office Hours
Appointments by email request
English, French, Russian, Spanish
Key Expertise
Pharmaceutical Policy, Health Economics, Data Integrity

About me

Dr. Leeza Osipenko is a Senior Lecturer in Practice. She joined the LSE Department of Health Policy in September 2018. She is CEO of a research organisation Consilium Scientific which focuses on the quality and integrity of evidence generation in clinical research. After completing her PhD in Systems Engineering in the US, Leeza moved to the UK and worked as Senior Research Fellow at the University of Warwick Medical School. This experience was followed by two years at a public sector consultancy, Optimity Matrix where she was a Principal Economist.

Leeza led NICE Scientific Advice between 2014 and 2018. She chaired over 150 advisory meetings at NICE and at the EMA and provided methodological, operational, and strategic leadership for the team which became well-known internationally. During those years Leeza represented NICE as a chief analyst at the Department of Health Appraisal Alignment Working Group. She is an expert in Health Technology Assessment. Currently, her academic work focuses on examining the status quo of clinical research, through quality improvement, transparency and methodological rigour. In particular, she is interested in clinical data integrity, health policy, applied clinical research, and clinical trial design. 

Leeza is currently leading on the LockedDown Project which is an international collaboration across 17 language groups to collect information on the experiences of students and staff impacted by the COVID-19 pandemic.



HP424 Pharmaceutical Economics and Policy
HP4C3E Economic Evaluation in Health Care
HP4C4E Systematic Review and Meta-analysis


Visiting Fellow, Institute for Global Development 
Board Member, HealthWatch-UK, a charity promoting science and integrity in healthcare

Expertise Details

health technology assessment; clinical trial methodology; drug pricing; applied clinical research methodology; NICE; drug approval; evidence-based medicine; cost-effectiveness analysis

My research